FY2025 EPS Estimates for CEL-SCI Lifted by Zacks Small Cap

CEL-SCI Co. (NYSE:CVM) – Research analysts at Zacks Small Cap upped their FY2025 earnings per share estimates for CEL-SCI in a research report issued to clients and investors on Monday, February 10th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.29) for the year, up from their previous forecast of ($0.38). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.38) per share. Zacks Small Cap also issued estimates for CEL-SCI’s FY2026 earnings at ($0.18) EPS.

Separately, StockNews.com initiated coverage on CEL-SCI in a research note on Sunday. They set a “sell” rating on the stock.

CEL-SCI Stock Up 11.3 %

NYSE CVM opened at $0.42 on Wednesday. The stock’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.80. The company has a market capitalization of $30.80 million, a P/E ratio of -0.81 and a beta of 0.69. CEL-SCI has a 52 week low of $0.33 and a 52 week high of $2.50. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62.

Institutional Trading of CEL-SCI

Large investors have recently added to or reduced their stakes in the company. Calton & Associates Inc. bought a new stake in CEL-SCI in the 3rd quarter worth approximately $50,000. Thoroughbred Financial Services LLC increased its stake in CEL-SCI by 40.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after acquiring an additional 54,900 shares during the last quarter. Plotkin Financial Advisors LLC bought a new stake in CEL-SCI in the 3rd quarter worth approximately $98,000. Finally, Geode Capital Management LLC increased its stake in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the last quarter. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.